Papaverine and its analogues have been advocated by a number of authors for the treatment of angina pectoris, and this study describes an attempt to evaluate the ethyl analogue of papaverine, ethaverine (diquinol) for this purpose. 
ETHA VERINE IN ANGINA PECTORIS of 25 patients. In all these trials with dioxyline phosphate a dosage of between 600 and 1200 mg. a day were given orally.
The marked coronary dilating activity of ethaverine in laboratory studies, the clinical studies on the action of papaverine and its derivatives in angina, together with its low toxicity, suggested a clinical trial of ethaverine in the treatment of angina pectoris. Its previous clinical use had been confined to spastic conditions of the intestinal, biliary, and urinary tracts (Adler, 1932; Goldstein, 1937; Ionescu-Militiade, 1932; Kottlors, 1934; Szentkiralyi, 1932) , to dysmenorrhcea (Wiesbader, 1933) , and to hypertension (Dobrzanski, 1935; Spychala, 1934) . No evidence of toxicity was noted in these trials. Berkesy (1932) described ethaverine as non-toxic and free from local irritation, even on subcutaneous injection. Dobrzanski (1935) remarked on its low toxicity, whilst Spychala (1934) described it as being two to three times less toxic than papaverine.
METHOD
Twenty-two patients suffering from angina of effort were treated during this trial. All described the characteristic pain of short duration brought on by exercise and relieved by rest and nitrites. Their ages ranged from 43 to 68, and the duration of symptoms was between one and six years in all except four patients. The blood pressure exceeded 170/100 in 18, and was above normal in all cases. The Wassermann reaction was negative, and the hamatological findings within normal limits in the whole series. Electrocardiograms were recorded for each patient before and after exercise; the exercise consisting of walking up and down two steps until pain was produced. Three patients had evidence of previous myocardial infarction and a further three showed bundle branch block. Nine patients had typical patterns of coronary insufficiency in the cardiogram with no definite evidence of infarction. Some of these showed further abnormalities after exercise. Four others had normal cardiograms at rest but showed alterations in the S-T segment after exercise. Attempts were made throughout the study to challenge the diagnosis and also the suitability of the patient for inclusion in this trial. All patients were ambulatory. One patient was excluded from the final analysis because she had an attack of severe precordial pain after five days' treatment with ethaverine, and treatment was stopped at her own request. Another failed to attend the clinic regularly. This left 20 patients who completed the trial and were available for analysis.
Two materials were compared-50-mg. capsules of ethaverine and indistinguishable capsules of lactose as controls. A dosage of two capsules four times daily (400 mg. of ethaverine daily) was employed, and the capsules were supplied in bottles each containing one week's supply. All patients received six pairs of bottles, numbered 1 to 6, to be taken consecutively, and of these, three contained ethaverine and three lactose. The pairs of bottles were mixed at random, and could only be identified by means of a cipher which was kept in a sealed envelope until the completion of the trial. Neither patient nor doctor knew the identity of the capsules. After twelve weeks' therapy some patients received further supplies of the capsules, but this time four-weekly periods were used instead of fortnightly.
A subjective evaluation was carried out by use of a daily report card on which the patient indicated by a cross the degree of pain he had during the day. No account was taken of weather changes, of mental stress, or of changes in habit, and the patient was allowed to take tablets of glyceryl trinitrate as required. (It was considered that as the patient acts as his own control the effect of these factors should, after an adequate period of time, cancel each other out and also as each patient received the capsules in a different order for the same period weather changes could also be neglected.)
Objective evaluation was attempted by the exercise tolerance test on those patients considered to be sufficiently well. After a half-hour rest the patient walked up and down two steps (Master etal., 1944) until the first symptoms of pain developed, and the number of trips over the steps was recorded.
Some of the patients were considered to be too ill or became too breathless to be subjected to exercise, and if any patient had suffered from an attack of angina during the hour prior to attending the clinic no test was undertaken at that visit.
Analysis of the daily report cards over the whole period of the trial (1517 days on ethaverine and 1487 days on placebo treatment) showed that while on treatment with ethaverine the patients reported 14*2 per cent of days free from pain, 44*4 per cent good days, 36 per cent average days, 5 4 per cent bad days, whilst during treatment with the control capsules they reported 1 31 per cent of days free from pain, 44*4 per cent good days, 36*3 per cent average days, and 6-2 per cent bad days. These results show no significant difference.
As approximate blood levels obtained by a photospectrometric technique showed the presence of ethaverine or a derivative in substantial amounts twenty-four hours after administration of three capsules, it was considered that there would be an accumulation of the drug in the blood. To allow for the cumulative effect the second week of treatment period of either lactose or ethaverine was analyzed apart from the first week. The result of this analysis showed no greater difference between periods of treatment and non-treatment than when both weeks were taken together.
Analysis of the exercise tolerance test showed that 932 " trips " were performed at the end of periods of ethaverine treatment, whilst 990 " trips " were performed after periods of control treatment (Table I) . No side-effects attributed to the drug were noted during the trial. CONCLUSIONS Under the conditions of the trial ethaverine had no greater effect than inert lactose control capsules on the prevention of pain due to angina of effort. Occasionally patients showed apparent marked improvement on ethaverine, but an approximately equal number showed a similar change on control capsules. No common characteristic marked those showing improvement.
Analysis at the end of three months' treatment showed substantially the same results as the final analysis. It is felt that any drug with a marked effect in angina pectoris should show its effect in three months, and this period was considered to be sufficient for a future preliminary assessment of a drug at one dosage level.
In spite of these negative results it was interesting to note that many of the patients claimed great benefit from the use of the capsules, whether drug or control. This emphasizes the importance of the " double blind method " for evaluation of a drug. Incidentally, it was found that the drug had no effect on the incidence of intermittent claudication in two patients, nor did it have any effect on the blood pressure of any of the patients. condition some weeks previously is not to be relied on, and a wrong conclusion on the part of the patient will make a large difference to the final result since each decision applies to a week or fortnight. These disadvantages can be minimized by using a daily record, as was used in this trial. Using this method the doctor should remind the patient at frequent intervals that he must record whether he had a good day or a bad day, and that in doing this he should take into account the number of, for instance, glyceryl trinitrate tablets he has consumed or the amount of exercise he has taken. The main objection to this method is that the patient's decision on a good day or bad day is not made against any fixed standard. After three days of no pain, for instance, a day which he would normally describe as a good day may seem to be a very bad day.
The close agreement between the results of the subjective and objective evaluation of ethaverine in this trial makes it improbabie that this drug has any effect at the dosage level used. In view, however, of the repeatedly confirmed action of papaverine and its derivatives on the coronary circulation in experimental animals, the effect of papaverine on the cardiogram in high dosage, as shown by Russek et al. (1950) , and the absence of toxicity, a dosage several times greater than we employed may produce beneficial effects on cases of angina pectoris.
SUMMARY
Under the conditions of this trial ethaverine in a dosage of 400 mg. daily was found to have no greater action on the pain experienced or the exercises performed by patients suffering from angina pectoris than inert lactose capsules.
Earlier records on the use of papaverine and its analogues in angina pectoris and methods of evaluating drugs in angina are briefly reviewed. Evaluation at a higher dosage level, and for longer periods of time, is considered worthy of trial.
